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Abstract
BACKGROUND: We have previously reported on the
cDNA microarray gene expression profiles of hepato-
cellular carcinomas (HCCs). Among the genes that
show prognostic significance and are overexpressed
in tumor compared with adjacent nontumorous liver,
transcript AA454543 may have potential for practical
use. Our aim is to validate the prognostic significance
of transcript AA454543 by alternative research meth-
ods and in a separate group of HCC patients.
METHODS AND RESULTS: The data of transcript
AA454543 derived from microarray analysis of 48 pa-
tients having curative partial hepatectomy (group 1)
were verified by quantitative reverse transcription poly-
merase chain reaction (r = 0.618, P < .001). A separate
sample set of HCCs obtained from 53 patients (group 2)
was examined and the association of AA454543
expression level with overall survival was again vali-
dated (P = .027). By Cox regression analysis, transcript
AA454543 [hazard ratio (HR) = 3.0, P = .017] and patho-
logic tumor node metastasis (pTNM) stage (HR = 3.3,
P = .010) were independent prognostic factors for
overall survival. The accuracy of prediction for 3-year
overall survival for transcript AA454543 (74.2%, P =
.001) and pTNM stage (76.4%, P = .001) was com-
parable as measured by the area under the receiver
operating characteristic curve. CONCLUSION: Tran-
script AA454543 is a potentially useful molecular prog-
nostic marker for overall survival after curative partial
hepatectomy for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is prevalent in Asia and
Africa and is among the five leading causes of cancer
deaths worldwide [1]. Surgical resection in the form of
partial hepatectomy or liver transplantation is the choice
for curative treatment of this malignant disease [2–5]. None-
theless, recurrence is still common after curative surgery and
the cumulative 5-year survival rate is less than 50% for partial
hepatectomy [6–9]. Thus, a prognostic marker is needed to
identify patients who are at high risk of recurrence and may
need aggressive adjuvant treatment. In general, pathologic
tumor node metastasis (pTNM) staging accurately predicts
patient long-term survival, but among patients with the same
pTNM stage, a difference in long-term survival is frequently
observed. As the behavior of HCC could be affected by genetic
composition and expression pattern, we decided to study the
gene expression difference between HCCs and their adjacent
nontumor liver in relation to patient outcome after hepatectomy
[10]. From our preliminary analysis of 48 patients, 1404 cDNA
clones showed at least four-fold difference from the mean and,
among these genes, transcript AA454543 was identified to
have significance in predicting long-term survival as it ranks
high in prognosis prediction and it has a high expression level in
tumors relative to nontumors.
The transcript AA454543 sequence (clone ID IMAGE:
838048; UniGene Cluster Hs.437039; accession BC043195)
is a 1703-bp mRNA with partial codons and was originally
cloned from the hypothalamus of the human brain. By se-
quence homologue search with the National Center for Bio-
technology Information (NCBI) BLAST, transcript AA454543
shows 95% identity over 1686 bp with AL035705, which is
the human DNA sequence from clone RP4-758N20 on chro-
mosome 1p31.3-32.2. Compared with the mouse genome,
transcript AA454543 shows 85% identity over 327 bp with
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AL929466, which is the DNA sequence on mouse chromo-
some 4. No known gene in the genomes of human, mouse,
and model organisms shows a high sequence homology with
the transcript AA454543 sequence.
In this study, we aimed at validation of prognostic signifi-
cance of transcript AA454543 by quantitative reverse tran-
scription polymerase chain reaction (RT-PCR) in the group
of patients from whom the cDNA microarray data were
derived and in a separate group of HCC patients. We also
studied the significance of transcript AA454543 in patient
survival in comparison with pathologic staging.
Patients and Methods
Patients and Samples
Forty-eight patients who underwent curative partial hepa-
tectomy during the period March 1999 to April 2000 at the
Queen Mary Hospital, Hong Kong were selected for the
initial study (group 1). The gene expression profile of these
48 patients had been studied by cDNA microarray [10]. To
validate the data obtained from cDNA microarray, in this
study, quantitative RT-PCR was performed in HCCs of this
group for the AA454543 expression. Another 53 HCC
patients (group 2) operated during the period April 2000 to
March 2002 in the same institute with the same inclusion
criteria were recruited for further validation study by RT-PCR
for transcript AA454543. This independent cohort of patients
(group 2) was used to confirm that the prognostic marker
works in general, and not only on the group of patients from
whom the data are derived (group 1) [11]. Patients were
included in this study if the pathologic examination of the
resected specimen showed a clear resection margin.
Patients were not selected if the pathologic examination
showed a mixture of other tumor cell types (e.g., cholangio-
carcinoma); if they had received chemotherapy before or
after resection; if they had undergone liver transplantation
instead of partial hepatectomy; if the resection was per-
formed for recurrence or palliative intent; or if the resection
was followed by hospital death. The clinico-pathologic data
of the two groups of patients were listed in Table 1. The age
of the patients ranged from 13 to 79 years, with a median
age of 52 years. There were 81 men and 20 women. Serum
hepatitis B surface antigen was positive in 92 patients
(91.1%). Tumors were staged according to the International
Union Against Cancer pathologic tumor lymph node metas-
tasis (pTNM) tumor classification, 1997 version [12], be-
cause the 2002 version did not clearly stratify survival of our
patients with advanced stages [13]. The pTNM staging for
HCC uses pathologic characteristics of tumors, including
size, number and location of tumor nodules, presence of
vascular invasion, perforation of visceral peritoneum, and
invasion of adjacent organs as criteria for T staging; regional
lymph node metastasis for N staging; and distant metastasis
for M staging. The patients were prospectively followed up
for recurrence of HCC. Recurrence was diagnosed based
on typical imaging findings in a contrast-enhanced com-
puted tomography scan and an increased serum AFP level.
In case of uncertainty, hepatic arteriography and a post-
Lipiodol computed tomography scan were performed, and, if
necessary, fine-needle aspiration cytology was used for
confirmation. Up to the date of analysis, 31 out of the total
101 patients succumbed to disease and the median survival
period was 12.5 months (range: 4.5–34.1 months). For the
remaining 70 patients, the median follow-up period was
33.4 months (range: 14.9–48.8 months).
Normal liver specimens from 30 organ donors (8 cadav-
eric and 22 live donors) were collected in transplant opera-
tions performed at the same institution from April 2000 to
December 2001 for cDNA microarray study and quantitative
RT-PCR assay for transcript AA454543. The organ donors
had no underlying liver diseases and were negative for
hepatitis B serology. The liver specimens were obtained
immediately on laparotomy to minimize the chance of DNA/
RNA alteration as a result of physiologic changes or physical
manipulation. Informed consents had been obtained for
specimen collection. The study protocol was approved by
the Ethics Committee of the University of Hong Kong.
Table 1. Clinico-Pathological Features of HCCs.
HCC Features Group 1 (n = 48) Group 2 (n = 53) Total n = 101
Age
Median 51 53 52
(Range) (13–73) (16–79) (13–79)
Gender
Male 36 45 81
Female 12 8 20
pTNM stage
Stages I and II 22 21 43
Stages III and IVa 26 32 58
Tumor size
V 5 cm 24 15 39
> 5 cm 24 38 62
Venous infiltration
Absence 27 21 48
Presence 21 32 53
Microsatellite nodules
Absence 26 25 51
Presence 22 28 50
Edmondson-Steiner
Grades 1 and 2 20 23 43
Grades 3 and 4 28 30 58
Serum AFP level
V 20 ng/ml 15 19 34
> 20 ng/ml 33 34 67
HBsAg
Positive 43 49 92
Negative 5 4 9
Underlining liver disease
Noncirrhosis 25 39 64
Cirrhosis 23 14 37
Disease mortality
Death 17 14 31
Alive 31 39 70
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Microarray Expression Study
The cDNA microarray slides were printed with about
23,000 cDNA clones including 17,400 genes. Samples,
RNA preparations, and hybridization protocols had been
established and described in detail previously [10, 14]. Data
were deposited into the Stanford Microarray Database
(http://genome-www5.stanford.edu/MicroArray/SMD/) [15].
The fluorescence signals were normalized by mean-
centering genes for each array and then mean-centering
each gene across all arrays. Only well-measured genes were
included in subsequent analyses, and defined as genes that
had a ratio of signal intensity to background noise of more
than 1.5-fold and net signal intensity to background of more
than 50 U, for either the Cy5-labeled sample or the Cy3-
labeled reference, in at least 50% of the tested samples. A
total of 1404 cDNA clones, with expression levels different by
at least four-fold from the mean in at least two samples, was
selected for further analyses by Cox regression.
Quantitative RT-PCR for Transcript AA454543
Quantitative RT-PCR was performed as described [16].
Briefly, the first-strand cDNA was synthesized from 0.5 mg of
total RNA using the High-Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA) following the manufacturer’s
instruction. Each 25-ml PCR reaction contained 1  PCR
buffer II; 5.5 mM MgCl2; 0.2 mM each of dATP, dCTP, and
dGTP; 0.4 mM dUTP; 0.625 U of AmpliTaq Gold; and 5 ml of
first-strand cDNA. Primer and probe reagents for 18S rRNA
(Pre-Developed TaqMan Assay Reagents; Applied Biosys-
tems) were used as the endogenous normalization control.
Primers and probe for transcript AA454543 were AA454543-F
(5V-ACC CAC ACA CAG CGC TCA C-3V), AA454543-R (5V-
CAA GCC GTA AAA CTT CTG CAT G-3V), and AA454543-P
(5V-6FAM AGT CAC TCT CAG CGG CCA TCG CCC A-3V).
Quantification was performed using the ABI Prism 7700 se-
quence detection system (Applied Biosystems). Transcript
quantification was performed in at least triplicates for every
sample, and the threshold line was usually set atRn = 0.1. The
relative amount of transcript AA454543 had been normalized
against the amount of control 18S and relative to the calibrator,
and expressed as DDCt, where DDCt = [Ct(AA454543) 
Ct(18S)] calibrator  [Ct(AA454543)  Ct(18S)] test sample.
Thecalibratorwas the sampleatwhich theamount of transcript
AA454543 was of baseline level of the sample series. The
relative amount of AA454543 was presented as the relative
fold difference in log 2 base scale.
Statistical Methods
Cox regression analyses with gene expression data as
continuous variables were computed to examine gene ex-
pression that was associated with the overall survival after
curative resection. The technical concern of microarray data
reproducibility was addressed by using quantitative RT-PCR
for validation. Correlation of expression data by microarray
and quantitative RT-PCR data was assessed by the Spear-
man correlation test. The association of transcript AA454543
expression and overall survival was validated in group 2
patients by quantitative RT-PCR.
The overall accuracy of using transcript AA454543 ex-
pression level for prognosis prediction was measured by the
area under the receiver operating characteristic curve, as
there could be limitations of using hazard ratio in gauging
the performance of a prognostic marker [17]. The prediction
power for 3 years was analyzed. Patients who were alive but
with less than 3 years of follow-up were excluded from the
prediction study. Thus, 59 patients, with 31 of them suc-
cumbing to disease, were included in this part of analysis.
The Youden index (sensitivity + specificity1) [18] was used
to determine the optimal cutoff point of transcript AA454543
expression for the prediction of 3-year overall survival. The
Youden index was employed to maximize the sensitivity
(true-positive fraction) and specificity (1  false-positive
fraction) of the prediction simultaneously.
The association of gene expression and pTNM stage with
patient outcome was examined by univariable and multivari-
able Cox proportional hazards regression with the forward
stepwise selection procedure. pTNM stage information was
categorical data. To ease interpretation, the gene expres-
sion data were modeled as categorical variable only in the
multivariable Cox regression to comprehend the hazard
ratios in a more interpretable scale for direct comparison
with pTNM stage. The transcript AA454543 expression data
were also modeled as categorical variable in the Kaplan-
Meier analyses.
The associations of transcript AA454543 expression
level with clinico-pathologic features were assessed by the
Spearman correlation and Mann-Whitney U test, where
appropriate. Differences were considered significant when
P value was less than 0.05. Statistical analyses were aided
by the SPSS version 11.0 software package (SPSS, Inc.,
Chicago, IL).
Additional Microarray Information
The microarray study was carried out following the
MIAME guidelines issued by the Microarray Gene Expres-
sion Data Group [19]. The original data are available in the
Stanford Microarray Database (http://genome-www5.
standord.edu). Information is also available from the authors
on request.
Results
Transcript AA454543 Expression and Overall Survival
In the cDNA microarray data, the transcript AA454543
ranks high in prognosis prediction (top 15) and in expression
level relative to nontumors (top 2) (Supplementary Table 1).
Higher transcript AA454543 level by cDNA microarray was
significantly associated with shorter overall survival [hazard
ratio (HR) = 1.8, 95% confidence interval (CI) 1.1–3.1, P =
.024] (Table 2). Quantitative RT-PCR was performed on the
HCC samples of the group 1 patients to verify the cDNA
microarray data. The two research methods demonstrated a
high concordance (Spearman correlation, r = 0.618,
P < .001). In group 2 patients, transcript AA454543 expres-
sion level as measured by quantitative RT-PCR showed a
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significant association with the overall survival (HR = 1.4,
95% CI 1.0–2.0, P = .027) (Table 2).
The two independent sample sets examined by two
different techniques both indicated that a higher expression
level of transcript AA454543 in HCC was associated with
poor overall survival after curative surgery. The two sample
sets were then included into Cox regression analyses with
transcript AA454543 expression level based on quantitative
RT- PCR data. The transcript AA454543 level was signifi-
cantly associated with overall survival in the combined data-
set (HR = 1.3, 95% CI 1.1–1.6, P = .008) (Table 2).
Prognosis by Transcript AA454543 Expression and
pTNM Stage
All patients in the two groups were included in the overall
survival analyses. The transcript AA454543 expression data
were based on quantitative RT-PCR method, and the pre-
diction power for overall survival was compared with pTNM
stage. The accuracy of using transcript AA454543 expres-
sion for predicting the 3-year overall survival rate was 74.2%
(95% CI 61.2–87.2%, P = .001) measured by the area under
the receiver operating characteristic curve (Figure 1). For
comparison, the accuracy of using pTNM stage for sur-
vival prediction was 76.4% (95% CI 64.2–88.5%, P = .001).
By Youden index, the optimal cutoff value of transcript
AA454543 expression to segregate patients into low- or
high-transcript AA454543 expression group was 7.05 (rela-
tive fold change in log 2 base). Using this cutoff value for
predicting patient outcome by transcript AA454543 expres-
sion, sensitivity and specificity were 80.6% and 67.9%,
respectively. When patients were dichotomized as early-
stage (stages I and II) or late-stage (stages III and IVa)
groups, sensitivity and specificity of prognosis prediction by
pTNM stage were 80.6% and 57.1%, respectively.
The Kaplan-Meier plot was used to further examine
prediction power by using the transcript AA454543 expres-
sion level alone, or together with the pTNM stage system in a
total of 101 patients. Using the Youden index as cutoff, there
were 43 patients in the low-transcript AA454543 expression
group (range: 0–7.02), and 58 patients in the high-transcript
AA454543 expression group (range: 7.08–11.50). By using
the transcript AA454543 level alone to segregate the
patients, the cumulative 3-year overall survivals for patients
with low- and high-transcript AA454543 levels were 86.0%
(37/43) and 56.9% (33/58), respectively (log-rank test,
P = .001) (Figure 2). The analysis was repeated based on
the transcript AA454543 level and pTNM stages of the
patients. The cumulative 3-year overall survivals was 96%
(24/25) for early-stage (stages I and II) patients with a low
transcript AA454543 level, 72.2% (13/18) for early-stage
patients with high transcript AA454543, 72.2% (13/18) for
late-stage (stages III and IVa) patients with low transcript
AA454543, and 50.0% (20/40) for late-stage patients with
high transcript AA454543 (log-rank test, P = .014).
By Cox regression analysis, transcript AA454543 expres-
sion data modeled as continuous variable were significantly
associated with the overall survival (Table 2). However, the
hazard ratios expressed in their natural scale illustrated only
the change in the risk of disease-related mortality associated
with a change of 1 U on the expression scale—a change too
small to be understood easily. To assist interpretation, the
gene expression data were modeled as categorical variable
to comprehend the hazard ratios in a more interpretable
scale (Table 3). The patients were segregated into low- or
high-transcript AA454543 expression groups similarly as in
the Kaplan-Meier analyses, using the Youden index to
determine the optimal cutoff value. The data were compared
with pTNM stage and liver cirrhosis (as the majority of the
patients was HBV-related, where liver cirrhosis might affect
patient outcome after hepatectomy). By univariable Cox
regression analysis, transcript AA454543 expression (HR =
3.9, 95% CI 1.6–9.6, P = .003) and late pTNM stage (HR =
4.2, 95% CI 1.7–10.3, P = .002) were significantly associ-
ated with the overall survival, but liver cirrhosis showed no
association with overall survival (P = .709). By multivariable
Cox regression analysis, only transcript AA454543 expres-
sion (HR = 3.0, 95% CI 1.2–7.5, P = .017) and late pTNM
stage (HR = 3.3, 95% CI 1.3–8.2, P = .010) were indepen-
dent prognostic factors for overall survival.
Transcript AA454543 Level in Liver Tissues
Transcript AA454543 expression was higher in the HCC
tissues compared to the nontumor liver tissues adjacent to
Table 2. Cox Regression Analyses for Overall Survival on Transcript
AA454543 Expression.*
Patients n Univariable Analysis
HR (95% CI) P
Group 1 48 1.8 (1.1–3.1) .024
Group 2 53 1.4 (1.0–2.0) .027
Groups 1 and 2 101 1.3 (1.1–1.6) .008
*The transcript AA454543 expression data were modeled as continuous
variable. The expression data were based on the microarray data in group 1
patients, and quantitative RT-PCR in group 2 patients and the combined
groups of patients.
Figure 1. The accuracy of prediction for overall survival was measured by the
area under the receiver operating characteristic curve. The ‘‘sensitivity’’ (true-
positive fraction) against ‘‘1  specificity’’ (false-positive fraction) was plotted
for transcript AA454543 expression level (range: 0–11.50) and pTNM stage
(I, II, III, and IVa), respectively.
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HCCs in the earlier observation based on the cDNA micro-
array approach. To validate the observation, we randomly
examined 93 (out of a total of 101) liver tissues adjacent to
HCCs using real-time quantitative RT-PCR to measure the
transcript levels. The results indicated that the HCCs dem-
onstrated a significantly higher transcript AA454543 level
(median: 7.21, range: 0–11.50) compared to that of liver
tissues adjacent to HCCs (median: 5.54, range: 1.26–10.13)
(P < .001).
The higher expression level in HCCs than the liver tissues
adjacent to HCCs could be interpreted as either transcript
AA454543 upregulation in HCCs or transcript AA454543
downregulation in liver tissues adjacent to HCCs. To distin-
guish the two situations, 30 normal liver tissues were exam-
ined. In normal livers, the transcript AA454543 transcript
was found to express at a low level (median: 5.31, range:
0–7.36), which was significantly lower than the HCCs
(P < .001) but not significantly different from the liver tissues
adjacent to HCCs (P = .382) (Figure 3).
Transcript AA454543 Expression and Clinico-Pathologic
Features
To better understand the significance of transcript
AA454543 expression, we analysed the association of tran-
script AA454543 expression level with the clinico-pathologic
parameters of the HCC patients. The upregulation of tran-
script AA454543 expression in tumor was significantly asso-
ciated with late pTNM stage (r = 0.299, P = .002), venous
infiltration (P < .001), microsatellite nodules (P = .016), and
high Edmondson-Steiner histologic grade (r = 0.276, P =
.005). The transcript AA454543 expression level in the tumor
was not significantly associated with tumor size, gender,
age, HBsAg positivity, serum AFP level, or liver cirrhosis.
The AA454543 expression level in nontumor liver tissues
was not significantly associated with pTNM stage, venous
infiltration, microsatellite nodules, Edmondson-Steiner histo-
logic grade, tumor size, gender, age, HBsAg positivity,
serum AFP level, or liver cirrhosis.
Figure 2. Kaplan-Meier overall survival plot. (A) All patients were categorized
into low- or high-transcript AA454543 expression groups. (B) Early-stage
(stages I and II) patients were further segregated according to transcript
AA454543 expression level. (C) Late-stage (stages III and IVa) patients were
further segregated according to the transcript AA454543 expression level.
Table 3. Cox Regression Analyses for Overall Survival on Transcript
AA454543 Expression and pTNM Stage.
Variables n Univariable Analysis Multivariable Analysis
HR (95% CI) P Adjusted HR (95% CI) P
Transcript AA454543*
Low level
(0–7.02)
43 1 1
High level
(7.08–11.50)
58 3.9 (1.6–9.6) 0.003 3.0 (1.2–7.5) 0.017
pTNM stagey
Early stages
(I and II)
43 1 1
Late stages
(III and IVa)
58 4.2 (1.7–10.3) 0.002 3.3 (1.3–8.2) 0.010
*The transcript AA454543 expression data were modeled as categorical
variable. The optimal cutoff value to segregate patients into low- or high-
transcript AA454543 expression group was determined by the Youden index,
which was 7.05.
yThe pTNM stage was modeled as categorical variable.
Figure 3. Transcript AA454543 expression in human liver samples, and
transcript level was quantitated by real-time RT-PCR.
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Discussion
Identification of patients with different risks after curative
treatment will be more and more important in disease man-
agement for patient benefit. The conventional pTNM stage
system has been proven informative for identifying patients
with different prognoses, and the current study demonstrated
that the molecular characteristics of HCC could further add
on the prediction power. Thus far, we evaluated the prog-
nostic significance of transcript AA454543 that was chosen
based on the analysis of our earlier microarray data. In
addition, its transcript level in the tumor is significantly higher
than the liver tissue adjacent to the tumor, which would be an
important consideration for clinical application and thus was
chosen for subsequent validation as molecular prognostic
marker. The aim of the study is to consolidate the signifi-
cance of the prognostic genes with the assay method quan-
titative RT-PCR, which is a technique that is readily available
in routine laboratories for practical use. In the current study,
we reported the prognostic significance of transcript
AA454543 whose expression level can predict survival for
HCC patients after curative hepatectomy. Transcript
AA454543 expression and pTNM stage were independent
prognostic factors for overall survival by multivariable Cox
regression analyses. Gene expression data, together with
pTNM stage, can help to provide a more accurate overall
survival prediction as illustrated in the Kaplan-Meier analyses
(Figure 2). Remarkably, the transcript AA454543 expression
(single gene data) and pTNM stage have similar accuracies
on prognosis prediction (74.2% and 76.4%, respectively).
Our ultimate target is to recruit more genes to increase the
accuracy for prognosis prediction.
With the microarray approach, we and the others have
reported the expression profiles of HCCs [10,14,20–25].
Expression of a-fetoprotein (AFP), cell cycle regulators,
genes associated with metabolism, and tumor dedifferentia-
tion status was associated with the molecular subtypes of
HCCs [10,14,20–25]. However, there have been few HCC
reports on the association of gene expressions with patient
outcomes. Notably, Iizuka et al. [26] reported the correlation
of gene expression profile with early intrahepatic recurrence.
There are fundamental differences between the present
study and that of the Iizuka et al. report. In that most of the
patients in Iizuka et al.’s study were HCV-related (22/33,
66.7%), whereas the patients in the present study were
mostly HBV-related (92/101, 91.1% in the present cohort).
Different etiological agents may have involved different
carcinogenesis pathways, resulting in different molecular
compositions and behaviors. Furthermore, we used the
overall survival of 3 years as end-point, whereas Iizuka et al.
used intrahepatic recurrence in the first year as the clinical
end-point for prognosis prediction. The prognostic genesmay
be different for prognosis of disease recurrence and overall
survival. Nonetheless, we had explored the original data
set by Iizuka et al. (http://surgery2.med.yamaguchi-u.ac.jp/
research/DNAchip/) and transcript AA454543 was not on the
probe set list. It would thus be important to evaluate if the
transcript AA454543 expression level can predict overall
survival in HCV-related HCCs.
The transcript AA454543 has not been well character-
ized and the biologic function is unknown. Notably, a
higher transcript AA454543 expression level in HCC was
associated with poor prognosis and aggressive tumor
features including late pTNM stage, venous infiltration,
microsatellite nodules, and high Edmondson-Steiner grade
(poor cellular differentiation). All these features were risk
factors for poor prognosis [27,28]. Importantly, venous
infiltration (presence of tumor cells in the vascular space)
and microsatellite nodules were features of tumor spread
[27]. Thus, the present data highly suggested the biologic
role of transcript AA454543 in tumor cell invasion: an
increased level of transcript AA454543 might enhance
the invasive ability of the tumor cells, subsequently result-
ing in venous infiltration and formation of microsatellite
nodules. In the hierarchical clustering analysis, transcript
AA454543 was found to cluster closely with the prolifera-
tion cluster, tightly with G-protein–coupled receptor and
zinc finger protein (Supplementary Figure 1), which play an
important role in coordinating cell cycle progression. These
genes that coexpressed with transcript AA454543 may
also help to provide a hint of the transcript AA454543
function. Further studies, for example, transfection experi-
ments to modulate transcript AA454543 level and examine
its effect on tumor cell invasion are needed to elucidate the
exact biologic role of AA454543 in disease progression.
Nonetheless, numerous functional elements including regu-
latory elements are non–protein-coding in the human
genome, and further bioinformatic analysis may also help
to understand the biologic significance [29–31].
The association of high-level transcript AA454543 with
tumor invasion further suggested that its prognostic informa-
tion may not only be limited to overall survival, but may also
be predictive for recurrence-free survival. The association of
AA454543 expression with recurrence-free survival was also
analyzed with Cox regression analysis (Supplementary
Tables 2 and 3). In the combined sample set (101 HCCs),
AA454543 expression was in fact significantly associated
with recurrence-free survival when the expression data were
modeled as continuous variables (P = .011) and categorical
variables (P = .018). However, independent analyses on the
two sample sets were inconclusive for the association of
AA454543 expression with recurrence-free survival, where
significant association was observed in group 1 patients (P =
.007) but not in group 2 patients. The discrepancy might be
due to the difference in recruitment time as group 2 patients
had a significantly shorter follow-up period. Furthermore, the
smaller patient number in the subgroup analysis also made
it difficult to achieve statistical significance. The association
of AA454543 with recurrence-free survival was not definite
with the present data, and therefore we intended not to draw
a conclusion at the current stage.
In the clinical samples, the transcript AA454543 level was
significantly higher in HCCs compared to the parallel liver
tissues adjacent to HCCs, and to normal livers. The tran-
script AA454543 level is informative in differentiating if the
liver tissue is neoplastic, in addition to providing prognostic
information. Preliminary in situ hybridization analysis on the
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cell origin of transcript AA454543 indicated that a cytoplas-
mic signal was observed in the neoplastic hepatocytes in
HCC tissue (Supplementary Figure 2), which further high-
lighted the potential of transcript AA454543 as a tumor
marker and therapeutic target in addition to the role as a
prognostic marker.
The present study indicates that the transcript AA454543
expression level can predict overall survival of patients after
curative partial hepatectomy. The current approach demon-
strates the power of expression profiles to identify prognostic
markers feasible for clinical application. It further consoli-
dates the prospect for considering unknown genes, instead
of only focusing on well-known genes with recognized bio-
logic contribution in carcinogenesis. Prognosis by genes of
unknown biologic roles has also been described in breast,
prostate, and lung cancers, and central nervous system
embryonal tumor [32–37]. This molecular marker provides
prognostic information in general (two independent cohort of
patients) and the prediction is independent of assay method
(microarray or quantitative RT-PCR). By quantitative RT-
PCR, this gene is feasible for routine laboratory assay.
Together with pTNM stage, it could help to improve progno-
sis prediction and disease management for patient benefit.
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